Psoriatic arthritis: Complexities, comorbidities and implications for the clinic

Expert Review of Clinical Immunology

Volumn 12, Issue 4, 2016, Pages 405-416

  Haroon, Muhammad ^a   FitzGerald, Oliver ^b,c  

^a University College Cork   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

comorbidities; psoriatic arthritis; treatmen

Indexed keywords

ABATACEPT; APREMILAST; DISEASE MODIFYING ANTIRHEUMATIC DRUG; JANUS KINASE INHIBITOR; USTEKINUMAB;

BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HOSPITAL; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; INFLAMMATORY BOWEL DISEASE; JOINT RADIOGRAPHY; MALIGNANT NEOPLASTIC DISEASE; MASS SCREENING; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PROGNOSIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); UVEITIS; ANIMAL; ARTHRITIS, PSORIATIC; INFLAMMATORY BOWEL DISEASES; NAIL; PATHOLOGY; SKIN; TREATMENT OUTCOME;

ANIMALS; ARTHRITIS, PSORIATIC; COMORBIDITY; HUMANS; INFLAMMATORY BOWEL DISEASES; NAILS; SKIN; TREATMENT OUTCOME; UVEITIS;

EID: 84958536471     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2016.1139453     Document Type: Review

References (93)

1. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573-577.
2. Taylor WJ. Epidemiology of psoriatic arthritis. Curr Opin Rheumatol. 2002;14:98-103.
3. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: A systematic review. J Rheumatol. 2008;35:1354-1358.
4. Liu J-T, Yeh H-M, Liu S-Y, et al. Psoriatic arthritis: Epidemiology, diagnosis, and treatment. World J Orthop. 2014;5(4):537-543. doi:10.5312/wjo.v5.i4.537.
5. Hukuda S, Minami M, et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol. 2001;28(3):554-559.
6. Wilson FC, Icen M, et al. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009;36(2):361-367.
7. CASPAR Study Group, Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-2673.
8. Gladman DD, Chandran V, Thavaneswaran A, et al. Psoriatic arthritis in Canadian clinical practice: the PsA assessment in rheumatology. J Rheumatol. 2012;39(9):1850-1853.
9. Tillett W, Costa L, Jadon D, et al. The ClASsification for Psoriatic ARthritis (CASPAR) criteria-a retrospective feasibility, sensitivity, and specificity study. J Rheumatol. 2012;39(1):154-156.
10. Rahman P, Nguyen E, Cheung C, et al. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol. 2001;28(5):1041-1044.
11. Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PsA)-an analysis of 220 patients. Q J Med. 1987;62:127-141.
12. Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42(12):1460-1468.
13. Gladman DD, Thavaneswaran A, Chandran V, et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70(12):2152-2154.
14. Haroon M, Kirby B, Fitzgerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736-740.
15. van der Linden MP, Le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62:3537-3546.
16. Haroon M, Gallagher P, Fitzgerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2014; doi:10.1136/annrheumdis-2013-204858. [Epub ahead of print].
17. Robinson PC, Brown MA. The window of opportunity: a relevant concept for axial spondyloarthritis. Arthritis Res Ther. 2014;16(3):109.
18. Coates LC, Aslam T, Al Balushi F, et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol. 2013;168(4):802-807. doi:10.1111/bjd.12190.
19. Tom BD, Chandran V, Farewell VT, et al. Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2). J Rheumatol. 2015;42(5):841-846.
20. Mease PJ, Gladman DD, Helliwell P, et al. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2014;71 (4):649-655.
21. McHugh NJ. Early Psoriatic Arthritis. Rheum Dis Clin North Am. 2015;41(4):615-622.
22. Haroon M, Winchester R, Giles JT, et al. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Annals Rheum Dis. 2014;Epub ahead of print. doi:10.1136/annrheumdis-2014-205461.
23. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis. 2005;64(Suppl 2):ii3-8.
24. Eder L, Chandran V, Pellet F, et al. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Annals Rheum Dis. 2012;71:50-55.
25. Winchester R, Minevich G, Steshenko V, et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum. 2012;64:1134-1144.
26. Fitz Gerald O, Haroon M, Giles JT, et al. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther. 2015;17(1):115.
27. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55-78.
28. Jamnitski A, Visman IM, Peters MJ, et al. Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis. Ann Rheum Dis. 2011;70:875-876.
29. Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997;40:1868-1872.
30. Mok CC, Kwok CL, Ho LY, et al. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum. 2011;63(5):1182-1189.
31. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003;42 (6):778-783.
32. Haroon M, Gallagher P, Heffernan E, et al. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol. 2014;41 (7):1357-1365.
33. Favarato MH, Mease P, Gonçalves CR, et al. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis. Clin Exp Rheumatol. 2014;32(2):182-187.
34. Stokes KY, Calahan L, Hamric CM, et al. CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation. Am J Physiol Heart Circ Physiol. 2009;296(3):H689-97.
35. Wu S, Li WQ, Han J, et al. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis Rheumatol. 2014;66(2):304-310.
36. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793-1801.
37. Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. Jama. 2011;305(24):2525-2531.
38. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. Oct. 2005 25;112(17):2735-2752.
39. Mok CC, Ko GT, Ho LY, et al. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken). 2011;63(2):195-202. doi:10.1002/acr.20363.
40. Raychaudhri SK, Chatteriee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8 (4):331-334.
41. Eder L, Jayakar J, Pollock R, et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis. 2013;72(12):1956-1961.
42. CARMA Project Collaborative Group, Castañeda S, Martín-Martínez MA, González-Juanatey C, et al. Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: baseline data of the CARMA Project. Semin Arthritis Rheum. 2015;44 (6):618-626.
43. Costa L, Caso F, Ramonda R, et al. Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res. 2015;61(1-2):147-153.
44. Belinchón I, Vanaclocha F, De La Cueva-Dobao P, et al. Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: Prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study. J Dermatolog Treat. 2015;26(4):318-325.
45. Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014;33 (6):833-839.
46. Bostoen J, Van Praet L, Brochez L, et al. A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. J Eur Acad Dermatol Venereol. 2014;28(4):507-511.
47. Sharma A, Gopalakrishnan D, Kumar R, et al. Metabolic syndrome in psoriatic arthritis patients: a cross-sectional study. Int J Rheum Dis. 2013;16(6):667-673.
48. Puig L, Strohal R, Husni ME, et al. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. J Dermatolog Treat. 2015;26(1):7-15.
49. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama. 2002;288:2709-2716.
50. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867.
51. Shen J, Shang Q, Li EK, et al. Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study. Arthritis Res Ther. 2015;17:75.
52. Costa L, Caso F, D'Elia L, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol. 2012;31(4):711-715.
53. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. World Health Organ Tech Rep Ser. 2000;894(ixii):1253.
54. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311(8):806-814.
55. National Center for Health Statistics. Health, United States. With Special Features on Socioeconomic Status and Health. Hyattsville (MD):U.S. Department of Health and Human Services; 2012; 2011.
56. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32(6):982-986.
57. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case control study. J Invest Dermatol. 2005;125(1):61-67.
58. Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol. 2007;87(6):506-509.
59. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome: a cross-sectional study. Dermatology. 2008;216(2):152-155.
60. Marino MG, Carboni I, De Felice C, et al. Risk factors for psoriasis: a retrospective study on 501 outpatients clinical records. Ann Ig. 2004;16(6):753-758.
61. Murray ML, Bergstresser P, Adams-Huet B, et al. Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. Clin Exp Dermatol. 2009;34(2):140-144.
62. Soltani-Arabshahi R, Wong B, Feng BJ, et al. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol. 2010;146(7):721-726.
63. Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71(8):1273-1277.
64. Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum. 2012; 71(8):1267-1272.
65. Tan E, Baker C, Foley P. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis. Australas J Dermatol. 2013;54(4):259-263. doi:10.1111/ajd.12044.
66. Yanaba K, Umezawa Y, Ito T, et al. Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients. Arch Dermatol Res. 2014;306(10):921-925. doi:10.1007/s00403-014-1495-1. Epub 2014 Sep 6.
67. Korkoliakou P, Christodoulou C, Kouris A, et al. Alexithymia, anxiety and depression in patients with psoriasis: a case-control study. Ann Gen Psychiatry. 2014;13(1):38.
68. Dowlatshahi EA, Wakkee M, Arends LR, et al. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134 (6):1542-1551.
69. Dommasch ED, Li T, Okereke OI, et al. Risk of depression in women with psoriasis: a cohort study. Br J Dermatol. 2015;173(4):975-980.
70. McDonough E, Ayearst R, Eder L, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014;41(5):887-896.
71. Kotsis K, Voulgari PV, Tsifetaki N, et al. Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care Res (Hoboken). 2012;64 (10):1593-1601.
72. Thomson CA, McColl A, Cavanagh J, et al. Peripheral inflammation is associated with remote global gene expression changes in the brain. J Neuroinflammation. 2014;11:73.
73. Rosenbaum JT. Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol. 2015;34(6):999-1002.
74. Rosenbaum JT. Nibbling away at the diagnosis of idiopathic uveitis. JAMA Ophthalmol. 2015;133(2):146-147.
75. Niccoli L, Nannini C, Cassara E, et al Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. Int J Rheum Dis. 2012;15(4):414-418 15.
76. Lambert JR, Wright V. Eye inflammation in psoriatic arthritis. Ann Rheum Dis. 1976;35:354-356.
77. Fraga NA, Oliveira Mde F, Follador I, et al. Psoriasis and uveitis: a literature review. An Bras Dermatol. 2012;87 (6):877-883.
78. Casarou-Catsari A, Katsambas A, Theodoropoulos P, et al. Ophthalmological manifestations in patients with psoriasis. Acta Derm Venereol. 1984;64:557-559.
79. Ijima S, Iwata M, Otsuka F. Psoriatic arthritis and hypopion-iridocyclitis. Dermatology. 1996;193:295-299.
80. Egeberg A, Khalid U, Gislason GH, et al. Association of Psoriatic Disease With Uveitis: A Danish Nationwide Cohort Study. JAMA Dermatol. 2015; doi:10.1001/jamadermatol. 2015. 1986. [Epub ahead of print].
81. Haroon M, O'Rourke M, Ramasamy P, et al. A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool). Ann Rheum Dis. 2014; doi:10.1136/annrheumdis-2014-205358. [Epub ahead of print].
82. Gross RL, Schwartzman-Morris JS, Krathen M, et al. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol. 2014;66(6):1472-1481.
83. Rohekar S, Tom BD, Hassa A, et al. Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum. 2008;58 (1):82-87.
84. Scarpa R, Manguso F, D'Arienzo A, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol. 2000;27:1241-1246.
85. Scher JU, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015;67(1):128-139. doi:10.1002/art.38892
86. Gulliver WP. Importance of screening for comorbidities in psoriasis patients. Expert Rev Dermatol. 2008;3(2):133-135.
87. Husted JA, Thavaneswaran A, Chandran V, et al. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol. 2013;40(8):1349-1356.
88. Ogdie A, Schwartzman S, Eder L, et al. Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol. 2014;41 (11):2315-2322.
89. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387-1394.
90. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;doi:10.1016/S0140-6736(15) 00347-5. [Epub ahead of print].
91. Lin VW, Ringold S, Devine EB. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: A Bayesian network meta-analysis. Arch Dermatol. 2012;148(12):1403-1410. doi:10.1001/2013.jamadermatol.238.
92. Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169(2):458-463.
93. Ademowo OS, Hernandez B, Collins E, et al. Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. Ann Rheum Dis. 2014;doi:10.1136/annrheumdis-2014-205417. [Epub ahead of print].